Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing better health and a brighter future to people worldwide.

The Investigator Initiated Research (IIR) programme supports innovative interventional, non-interventional, and basic science studies that address important medical and scientific questions related to Takeda's compounds and IIR areas of interest.

Current areas of interest: Transplant, Hereditary Angioedema, Gastroenterology, Neuroscience, Rare Hematology, Rare Metabolic Diseases, Plasma Derived Therapies, Oncology.

IIR is defined as unsolicited, independent research where the investigator or the institution (academic, private, or governmental) serves as the Sponsor and Takeda provides support in the form of study drug and/or funding. Takeda is not the sponsor of an IIR. The investigator and institution/organisation assume all legal and regulatory responsibilities as a sponsor-investigator.

There are no deadlines for submissions.

Applications may be from any suitable research facility or organisation in the world. Eligible recipients include universities, medical schools, hospitals, academic medical centres, physician groups organised as a legal entity, hospice centres, research foundations, government departments and agencies that are authorised to receive funds for research.

In case of interest please click on "m'interessa"  and we will contact you.